Drug manufacturer Johnson & Johnson this afternoon announced conditions on 340B sales on 29 products—including several of its top-selling drugs—when hospitals use contract pharmacies. Grantees are exempt from the requirements, which take effect May 2.
J&J’s mid-day notice to customers made it the 16th manufacturer to adopt such a policy. It came less than a week after Gilead announced restrictions on 340B pricing on its branded hepatitis C treatments when hospital and grantee covered entities use contract pharmacies. This is a developing story. We will have in-depth coverage of J&J’s new policy in Tuesday’s issue.